Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 3/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3656180 | 0.90 | TSHR (0.62) | TSHRKCNH2KCNJ1IDO1LOXL2 | |
| SCHEMBL7758238 | 0.84 | TSHR (0.55) | TSHRKCNH2KCNJ1IDO1LOXL2 | |
| SCHEMBL4586250 | 0.84 | TSHR (0.65) | TSHRKCNH2KCNJ1IDO1LOXL2 | |
| SCHEMBL8328188 | 0.84 | TSHR (0.55) | TSHRKCNH2KCNJ1IDO1LOXL2 | |
| SCHEMBL7049974 | 0.84 | TSHR (0.55) | TSHRKCNH2KCNJ1IDO1LOXL2 | |
| SCHEMBL6141174 | 0.81 | IDO1 (0.63) | TSHRIDO1LOXL2AKR1C3ALDH1A1 | |
| SCHEMBL1165330 | 0.81 | TSHR (0.51) | TSHRKCNH2KCNJ1IDO1LOXL2 | |
| SCHEMBL7931694 | 0.80 | IDO1 (0.53) | TSHRIDO1AKR1C3ALDH1A1CYP2C19 | |
| SCHEMBL3292782 | 0.80 | TSHR (0.75) | TSHRKCNH2KCNJ1IDO1LOXL2 | |
| SCHEMBL378396 | 0.79 | TSHR (0.58) | TSHRKCNH2KCNJ1IDO1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534823-A4 | THE USE OF ISOCYANATE LINKERS TO MAKE HYDROLYZABLE ACTIVE AGENT BIOPOLYMER CONJUGATES | BIOMARIN PHARM INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20060029586-A1 | Use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates | BIOMARIN PHARMACEUTICAL INC. | 2006-02-09 | — | — | US | disclosed |
| WO-2005007663-A9 | FLUOROGENIC ENZYME SUBSTRATES AND USES THEREOF | IRM LLC (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050153306-A1 | Fluorogenic enzyme substrates and uses thereof | IRM LLC (BM) | 2005-07-14 | — | — | US | disclosed |
| EP-1534823-A2 | THE USE OF ISOCYANATE LINKERS TO MAKE HYDROLYZABLE ACTIVE AGENT BIOPOLYMER CONJUGATES | BioMarin Pharmaceutical Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005007663-A2 | FLUOROGENIC ENZYME SUBSTRATES AND USES THEREOF | IRM LLC (BM) | 2005-01-27 | — | — | WO | disclosed |
| US-20040176270-A1 | Use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates | BIOMARIN PHARMACEUTICAL INC. | 2004-09-09 | — | — | US | disclosed |
| WO-2004008101-A2 | THE USE OF ISOCYANATE LINKERS TO MAKE HYDROLYZABLE ACTIVE AGENT BIOPOLYMER CONJUGATES | BIOMARIN PHARMACEUTICAL INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-0776330-B1 | PHOTOLABILE COMPOUNDS AND METHODS FOR THEIR USE | AFFYMAX TECH NV (AN) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002099078-A2 | FUNCTIONAL PROTEOMIC PROFILING | IRM LLC (BM) | 2002-12-12 | — | — | WO | disclosed |
| US-5874589-A | Methods for synthesizing diverse collections of tetramic acids and derivatives thereof | GLAXO WELLCOME, INC. (US) | 1999-02-23 | — | — | US | disclosed |
| US-5846839-A | Methods for hard-tagging an encoded synthetic library | GLAXO GROUP LIMITED (GB) | 1998-12-08 | — | — | US | disclosed |
| US-5739386-A | PHOTOCLEAVABLE LINKING GROUPS IN SOLID PHASE SYNTHESIS | AFFYMAX TECHNOLOGIES N.V. (GB) | 1998-04-14 | — | — | US | disclosed |
| WO-1997041093-A1 | METHODS FOR THE SYNTHESIS OF FMOC PROTECTED AMINES | AFFYMAX TECHNOLOGIES N.V. (GB) | 1997-11-06 | — | — | WO | disclosed |
| EP-0776330-A2 | PHOTOLABILE COMPOUNDS AND METHODS FOR THEIR USE | AFFYMAX TECHNOLOGIES N.V. (AN) | 1997-06-04 | — | — | EP | disclosed |
| US-5549974-A | IMMOBILIZATION | AFFYMAX TECHNOLOGIES NV (AN) | 1996-08-27 | — | — | US | disclosed |
| WO-1996000148-A1 | METHODS FOR THE SOLID PHASE SYNTHESIS OF THIAZOLIDINONES, METATHIAZANONES, AND DERIVATIVES THEREOF | AFFYMAX TECHNOLOGIES N.V. (AN) | 1996-01-04 | — | — | WO | disclosed |
| WO-1996000378-A1 | PHOTOLABILE COMPOUNDS AND METHODS FOR THEIR USE | AFFYMAX TECHNOLOGIES N.V. (AN) | 1996-01-04 | — | — | WO | disclosed |
| WO-1995018971-A1 | METHODS FOR THE SOLID PHASE SYNTHESIS OF GLYCOCONJUGATES | AFFYMAX TECHNOLOGIES N.V. (NL) | 1995-07-13 | — | — | WO | disclosed |
| US-5420328-A | Esterification with alcohol and hydrolysis | AFFYMAX TECHNOLOGIES, N.V. (AN) | 1995-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153306-A1 | Fluorogenic enzyme substrates and uses thereof | PEPD, DNPEP, PREP | TSHR 3079/4885KCNH2 4679/4885KCNJ1 4724/4885 |
| US-20040176270-A1 | Use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates | SLC3A2, IPO7, SLC47A1 | TSHR 4643/4885KCNH2 1571/4885KCNJ1 2192/4885 |
| US-20060029586-A1 | Use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates | SLC3A2, SLC43A1, IPO7 | TSHR 4607/4885KCNH2 1399/4885KCNJ1 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.